Immune checkpoint inhibitors may be influenced by specific gut microbiome compositions in patients with urothelial carcinoma.
Certain gut microbiome compositions are associated with enhanced antitumor immunity and improved responses to immune checkpoint inhibitors.
Early studies indicate that specific microbial groups can influence immune system functions such as T cell priming and cytokine production.
Methods like , probiotic supplementation, and dietary changes have shown potential in modifying the gut microbiome to enhance outcomes.
Transplanting taxa from immunotherapy responders into treatment-naive or prior nonresponders may lead to beneficial effects.
Ongoing clinical trials are exploring the role of gut microbiome manipulation in improving immunotherapy results for urothelial carcinoma patients.
Simplified
Urothelial carcinoma (UC) remains a common cancer with significant morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) have helped revolutionize the treatment of UC, and there is growing evidence suggesting the crucial role of the gut microbiome in immune system function influences outcomes in this disease. Herein, we review the preclinical basis for how manipulation of the gut microbiome may alter the efficacy of immunotherapy for patients with cancer, highlight interventions optimizing gut microbiome diversity currently in use, review recent and ongoing clinical trials supporting the role of the gut microbiome in improving immunotherapy outcomes, and discuss clinical implications to improve outcomes for UC patients with immunotherapy in the real world. There is growing evidence that suggests that specific gut microbiome compositions significantly modulate the host immune system and response to ICIs. Early studies have shown that certain microbial taxa enhance antitumor immunity by influencing T cell priming, dendritic cell activation, and cytokine production. (FMT), probiotic supplementation, and dietary modulation have emerged as promising methods to alter microbiomes to improve immunotherapy outcomes. Taxa from positive immunotherapy responders across a variety of cancers demonstrate beneficial effects when transplanted into both treatment-naive or prior nonresponders. Increasing evidence suggests that the gut microbiome plays a crucial role in cancer care, particularly when patients are treated with immunotherapy. Future studies are needed to better understand the underlying mechanisms. While some studies are currently underway to explore gut manipulation for patients with UC, more studies are needed to investigate the potential to convert nonresponders into responders through microbiome manipulation.
Key numbers
1.8×
1.8× Longer Recurrence-Free Interval
In a trial of 58 patients with superficial bladder cancer.
66.7%
66.7% 1-Year Progression-Free Survival
Preliminary results from the TACITO trial in metastatic renal cell carcinoma.
9 of 10
9 of 10 Treatment-Naive Patients Responded
In a study involving 10 patients refractory to PD-1 blockade.
Full Text
We can’t show the full text here under this license.
